Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis

• Market Cap: €1.36B
• Dividend Yield: 3.12%
• Average Volume (3M): 31.21K
• Price to Earnings (P/E): 39.5
• Beta (1Y): 1.20
• Revenue Growth: 15.89%
• EPS Growth: 14.62%
• Country: DE
• Employees: 1,085
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Devices
• EPS (TTM): 0.47
• Shares Outstanding: 21,171,932
• 10 Day Avg. Volume: 27,583
• 30 Day Avg. Volume: 31,208
• PEG Ratio: 1.20
• Price to Book (P/B): 7.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 29.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €67.55
• Price Target Upside: 3.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 78 Outperform
• Price Target: €75.00 ▲(14.77%Upside)

The overall score is driven by a strong financial performance and positive technical indicators. The company's financial health is solid, with impressive revenue growth and cash flow generation, which supports future growth. Technical analysis shows strong bullish momentum, although the stock is approaching overbought levels. The valuation appears stretched, with a high P/E ratio, but this is partially offset by the dividend yield.

Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model

Company Description

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) is a leading German company specializing in the development, production, and sale of isotope technology components for medical, scientific, and industrial applications. The company's core products and services include radiopharmaceuticals, radiation therapy devices, and industrial radiometry equipment. Operating globally, Eckert & Ziegler serves clients in healthcare, research, and industrial sectors, providing innovative solutions for cancer treatment, diagnostic imaging, and radiation measurement.

How the Company Makes Money

Eckert & Ziegler generates revenue through the sale of its radiopharmaceuticals for nuclear medicine, which are used in diagnostic imaging and cancer therapy. The company also earns income from its radiation therapy devices, which are utilized in hospitals and clinics for treating various cancers. Additionally, Eckert & Ziegler's industrial segment provides radiation measurement and imaging solutions for a variety of industries. Significant partnerships with healthcare institutions and research organizations enhance its market reach, further contributing to its earnings.

Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview

Summary

Eckert & Ziegler Strahlen und Medizintechnik exhibits solid financial health with strong revenue growth, robust profitability margins, and a stable balance sheet. Cash flow generation is impressive, supporting future investment and growth opportunities. Continued focus on cost management and leveraging efficiencies will further enhance financial performance.

Income Statement

The company demonstrates strong revenue growth with a 20.22% increase from 2023 to 2024. Gross profit margin improved slightly, indicating good cost management. However, the net profit margin, while positive, suggests room for improvement in controlling expenses. EBIT and EBITDA margins remained robust, enhancing overall profitability.

Balance Sheet

The balance sheet is stable, with a solid equity ratio of 50.51% and a manageable debt-to-equity ratio of 0.25, indicating prudent financial leverage. Return on equity is healthy, reflecting efficient use of equity capital. The consistent growth in stockholders' equity further supports financial stability.

Cash Flow

Cash flow analysis shows a significant increase in free cash flow, with a 133.83% growth from 2023 to 2024, highlighting improved cash generation capabilities. The operating cash flow to net income ratio is strong, indicating effective conversion of income to cash. Free cash flow to net income ratio also underscores efficient cash management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
295.85M	246.09M	222.26M	180.44M	176.14M
	Gross Profit
143.16M	116.34M	106.78M	91.08M	86.53M
	EBIT
61.07M	47.00M	46.97M	46.03M	35.24M
	EBITDA
80.96M	59.67M	57.90M	56.68M	43.05M
	Net Income Common Stockholders
33.28M	26.30M	29.28M	34.53M	21.29M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
118.36M	68.00M	82.70M	95.02M	88.61M
	Total Assets
442.40M	439.36M	416.84M	347.73M	292.00M
	Total Debt
55.34M	56.30M	49.59M	26.97M	20.40M
	Net Debt
-62.88M	-11.69M	-33.11M	-66.69M	-67.07M
	Total Liabilities
217.18M	215.27M	203.21M	155.20M	143.08M
	Stockholders Equity
223.45M	222.18M	212.07M	187.39M	147.82M
Cash Flow		Free Cash Flow
49.38M	21.12M	3.17M	5.00M	27.88M
	Operating Cash Flow
66.57M	46.95M	34.30M	33.85M	36.79M
	Investing Cash Flow
-16.59M	-42.74M	-41.04M	-23.59M	-13.35M
	Financing Cash Flow
-9.99M	-9.28M	-5.71M	-6.06M	-12.96M

Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Positive. The current price of 65.35 is above the 20-day moving average (MA) of 64.15, above the 50-day MA of 59.04, and above the 200-day MA of 50.01, indicating a bullish trend. The MACD of 1.86 indicates Negative momentum. The RSI at 57.24 is Neutral, neither overbought nor oversold. The STOCH value of 78.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EUZ.

Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EUZ	78 Outperform	€1.36B	39.51	17.48%	3.12%	15.89%	14.62%
COP	64 Neutral	€1.16B	33.04	5.26%	4.53%	-2.84%	-24.28%
FYB	63 Neutral	€479.59M	5.89	-26.06%	―	-10.32%	-250.76%
BIO3	58 Neutral	€1.39B	44.96	-4.72%	0.27%	-18.82%	-113.85%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
BIO	50 Neutral	€1.39B	64.15	-4.72%	0.10%	-18.82%	-113.85%
EVT	49 Neutral	€1.31B	―	-20.51%	―	1.50%	-127.76%